Quantum Genesis AI Corp. (OTC: QGAI), a San Diego-based technology company focused on artificial intelligence and computational modeling, has issued a statement regarding the Caveat Emptor designation placed on its securities by OTC Markets Group on February 12, 2026. The designation, which warns investors to exercise caution, has prompted the company to seek clarification and initiate a formal review process.
Since the designation, Quantum Genesis AI has made several attempts to communicate with OTC Markets to understand the basis for the decision. OTC Markets indicated the designation relates to a “public interest concern,” though further details were not provided. The company has requested additional clarification and stated its intention to continue cooperating with OTC Markets to address the matter. According to the company, OTC Markets recently informed it that a formal review request may be filed starting March 13, 2026. Quantum Genesis AI intends to engage at the earliest opportunity to initiate that process.
“We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. “Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”
The Caveat Emptor designation is a red flag for investors, often indicating potential issues such as stock promotions, lack of current information, or other public interest concerns. For a company like Quantum Genesis AI, which aims to advance technologies at the intersection of AI and computational modeling, the designation could affect investor confidence and stock liquidity. The company’s commitment to transparency and cooperation with OTC Markets is crucial in resolving the designation and restoring market confidence.
Quantum Genesis AI remains focused on its strategy of leveraging data-driven tools for research and technology development across emerging sectors. The company has emphasized its dedication to maintaining transparency with shareholders and the broader investment community. As the review process unfolds, Quantum Genesis AI intends to provide updates as additional information becomes available. For more information, visit the company’s website at www.qgaicorp.com and its profile on OTC Markets at www.otcmarkets.com/stock/QGAI.
The company’s response underscores the importance of regulatory compliance and transparent communication in the over-the-counter markets. Investors will be watching closely to see how the situation develops and whether the company can successfully address the concerns raised by OTC Markets.
